International Patent: IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING CD19

GENEVA, Aug. 14 -- ABLYNX N.V. filed a patent application (EP2026/052912) for “IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING CD19”. With publication no. WO/2026/167016, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61P 35/00

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....